{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T07:04:49Z","timestamp":1775372689350,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejmech.2021.113971","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T23:23:57Z","timestamp":1635895437000},"page":"113971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Antitumor activity of novel POLA1-HDAC11 dual inhibitors"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8813-8922","authenticated-orcid":false,"given":"Sabrina","family":"Dallavalle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6838-7753","authenticated-orcid":false,"given":"Loana","family":"Musso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Cincinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Darwiche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5731-3396","authenticated-orcid":false,"given":"Silvia","family":"Gervasoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Vistoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario B.","family":"Guglielmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"La Porta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Pizzulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Modica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Prosperi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5366-6020","authenticated-orcid":false,"given":"Giacomo","family":"Signorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Colelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cardile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Fucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egildo Luca","family":"D'Andrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assunta","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113971_bib1","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-2399","article-title":"Combining molecularly targeted agents: is more always better?","volume":"23","author":"Sundar","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113971_bib2","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.2174\/0929867325666180607094856","article-title":"Dual inhibitors as a new challenge for cancer multidrug resistance treatment","volume":"26","author":"Stankovi\u0107","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113971_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100682","article-title":"Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors","volume":"50","author":"Dallavalle","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2021.113971_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12272-012-0221-9","article-title":"Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery","volume":"35","author":"Seo","year":"2012","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.ejmech.2021.113971_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-biochem-061516-044709","article-title":"Eukaryotic DNA replication fork","volume":"86","author":"Burgers","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2021.113971_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni.3409","article-title":"DNA polymerase-\u03b1 regulates the activation of type I interferons through cytosolic RNA: DNA synthesis","volume":"17","author":"Starokadomskyy","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2021.113971_bib7","doi-asserted-by":"crossref","first-page":"14013","DOI":"10.1093\/nar\/gku1209","article-title":"Structural basis for inhibition of DNA replication by aphidicolin","volume":"42","author":"Baranovskiy","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2021.113971_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.intimp.2018.12.006","article-title":"Checkpoint-modulating immunotherapies in tumor treatment: targets, drugs, and mechanisms","volume":"67","author":"Sun","year":"2019","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejmech.2021.113971_bib9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nchembio.2082","article-title":"The anti-tumor toxin CD437 is a direct inhibitor of DNA Polymerase \u03b1","volume":"7","author":"Han","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.113971_bib10","series-title":"The Retinoids, Biology","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113971_bib11","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1158\/0008-5472.CAN-03-2763","article-title":"A\u00a0Retinoid-related molecule that does not bind to classical retinoid receptors potently induces apoptosis in human prostate cancer cells through rapid caspase activation","volume":"64","author":"Keedwell","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113971_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/157339406776872852","article-title":"Mechanism of action and therapeutic potential of novel adamantyl retinoid-related molecules","volume":"2","author":"Piedrafita","year":"2006","journal-title":"Curr. Cancer Ther. Rev."},{"key":"10.1016\/j.ejmech.2021.113971_bib13","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1124\/mol.106.023614","volume":"70","author":"Parrella","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113971_bib14","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1021\/jm049440h","article-title":"Synthesis and structure\u2212activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity","volume":"48","author":"Cincinelli","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113971_bib15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/CAD.0000000000000511","article-title":"Antitumor activities of the synthetic retinoid ST1926 in two-dimensional and three-dimensional human breast cancer models","volume":"28","author":"Aouad","year":"2017","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejmech.2021.113971_bib16","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/ijc.29407","article-title":"ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model","volume":"137","author":"Nasr","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2021.113971_bib17","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/ijc.29886","article-title":"The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma","volume":"138","author":"Basma","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2021.113971_bib18","first-page":"39","article-title":"Mechanism of action of the atypical retinoid ST1926 in colorectal cancer: DNA damage and DNA polymerase \u03b1","volume":"8","author":"Abdel-Samad","year":"2018","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ejmech.2021.113971_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104253","article-title":"Novel adamantyl retinoid-related molecules with POLA1 inhibitory activity","volume":"104","author":"Cincinelli","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113971_bib20","first-page":"1954","article-title":"Epigenetic mechanisms and the hallmarks of cancer: an intimate affair","volume":"10","author":"Darwiche","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ejmech.2021.113971_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bioorg.2016.05.005","article-title":"Inhibitors of histone deacetylase as antitumor agents: a critical review","volume":"67","author":"Manal","year":"2016","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113971_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","article-title":"Inside HDACs with more selective HDAC inhibitors","volume":"121","author":"Roche","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113971_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41577-019-0151-6","article-title":"Epigenetic regulation of the innate immune response to infection","volume":"19","author":"Zhang","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2021.113971_bib24","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1016\/j.jchromb.2009.08.001","article-title":"Development and validation of a liquid chromatography\u2013tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantyl retinoid derivative, in plasma of patients in a Phase I study","volume":"877","author":"Sala","year":"2009","journal-title":"J.\u00a0Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ejmech.2021.113971_bib25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1593\/neo.05127","article-title":"Development of resistance to the atypical retinoid, ST1926, in the lung carcinoma cell line H460 is associated with reduced formation of DNA strand breaks and a defective DNA damage response","volume":"7","author":"Zuco","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejmech.2021.113971_bib26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases","volume":"6","author":"Bradner","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.113971_bib27","doi-asserted-by":"crossref","first-page":"110607","DOI":"10.1016\/j.biopha.2020.110607","article-title":"HDAC11: a rising star in epigenetics","volume":"131","author":"Liu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2021.113971_bib28","first-page":"54","article-title":"HDAC11 is a regulator of diverse immune functions","volume":"1861","author":"Yanginlar","year":"2018","journal-title":"BBA-Gene Regulatory Mechanisms"},{"key":"10.1016\/j.ejmech.2021.113971_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-61295-6","article-title":"Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2","volume":"10","author":"Bora-Singhal","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113971_bib30","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.bmcl.2018.05.021","article-title":"Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11","volume":"28","author":"Martin","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113971_bib31","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1021\/acschembio.9b00292","article-title":"Activity-guided design of HDAC11-specific inhibitors","volume":"14","author":"Son","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.113971_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/adts.201800191","article-title":"Molecular mechanisms of DNA replication and repair machinery: insights from microscopic simulations","volume":"2","author":"Maffeo","year":"2019","journal-title":"Adv Theory Simul"},{"key":"10.1016\/j.ejmech.2021.113971_bib33","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.113971_bib34","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.0307708100","article-title":"Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1","volume":"101","author":"Gui","year":"2004","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2021.113971_bib35","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s12272-015-0571-1","article-title":"Histone deacetylase inhibitors in hematological malignancies and solid tumors","volume":"38","author":"Chun","year":"2015","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.ejmech.2021.113971_bib36","first-page":"1609","article-title":"The role of Pin1 in the development and treatment of cancer Arch","volume":"39","author":"Min","year":"2016","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejmech.2021.113971_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12964-019-0352-4","article-title":"Genomic and non-genomic pathways are both crucial for peak induction of neurite outgrowth by retinoids Cell","volume":"17","author":"Khatib","year":"2019","journal-title":"Commun signal"},{"key":"10.1016\/j.ejmech.2021.113971_bib38","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cbin.10834","article-title":"Histone deacetylase 11 suppresses p53 expression in pituitary tumor cells","volume":"41","author":"Wang","year":"2017","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ejmech.2021.113971_bib39","first-page":"983","article-title":"Inhibition of histone deacetylase 11 promotes human liver cancer cell apoptosis","volume":"11","author":"Gong","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ejmech.2021.113971_bib40","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.celrep.2020.01.067","article-title":"Physiological tolerance to ssDNA enables strand uncoupling during DNA replication","volume":"30","author":"Ercilla","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2021.113971_bib41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.chembiol.2017.03.008","article-title":"HDAC inhibitor-induced mitotic arrest is mediated by Eg5\/KIF11 acetylation","volume":"24","author":"Nalawansha","year":"2017","journal-title":"Cell Chemical Biology"},{"key":"10.1016\/j.ejmech.2021.113971_bib42","article-title":"HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes","author":"Nunez-Alvarez","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2021.113971_bib43","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1002\/ijc.27876","article-title":"HDAC11 is a novel drug target in carcinomas","volume":"132","author":"Deubzer","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2021.113971_bib44","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1073\/pnas.1815365116","article-title":"HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2","volume":"116","author":"Cao","year":"2019","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2021.113971_bib45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbagrm.2017.12.002","article-title":"HDAC11 is a regulator of diverse immune functions","volume":"1861","author":"Yanginlar","year":"2018","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"10.1016\/j.ejmech.2021.113971_bib46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cyto.2016.01.010","article-title":"Anti-metastatic functions of type 1 interferons: foundation for the adjuvant therapy of cancer","volume":"89","author":"Ortiz","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.ejmech.2021.113971_bib47","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2021.113971_bib48","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/jir.2014.0157","article-title":"Potentials of interferon therapy in the treatment of pancreatic cancer","volume":"35","author":"Booy","year":"2015","journal-title":"J.\u00a0Interferon Cytokine Res."},{"key":"10.1016\/j.ejmech.2021.113971_bib49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2014.11.008","article-title":"The use of interferon in melanoma patients: a systematic review","volume":"26","author":"Di Troli","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2021.113971_bib50","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons \u03b1 and \u03b2 in cancer: therapeutic opportunities from new insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.113971_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.554570","article-title":"Epigenetic alterations and biomarkers for immune checkpoint inhibitors-current standards and future perspectives in malignan pleural mesothelioma treatment","volume":"10","author":"Yoshikawa","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejmech.2021.113971_bib52","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.bmc.2012.01.042","article-title":"New retinoid derivatives as back-ups of Adarotene","volume":"20","author":"Giannini","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113971_bib53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ijc.30412","article-title":"Promising in\u00a0vivo efficacy of the BET bromodomain inhibitor OTX015\/MK-8628 in malignant pleural mesothelioma xenografts","volume":"140","author":"V\u00e1zquez","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2021.113971_bib54","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking","volume":"267","author":"Jones","year":"1997","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113971_bib55","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jmgm.2005.12.005","article-title":"Automatic atom type and bond type perception in molecular mechanical calculations","volume":"25","author":"Wang","year":"2006","journal-title":"J.\u00a0Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2021.113971_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11262","article-title":"Insights into the activation mechanism of class I HDAC complexes by inositol phosphates","volume":"7","author":"Watson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.113971_bib57","doi-asserted-by":"crossref","first-page":"W368","DOI":"10.1093\/nar\/gki464","article-title":"H++: a server for estimating pKas and adding missing hydrogens to macromolecules","volume":"33","author":"Gordon","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2021.113971_bib58","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","article-title":"Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice","volume":"22","author":"Thompson","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2021.113971_bib59","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1021\/acs.jmedchem.8b01087","article-title":"Characterization of histone deacetylase 8 (HDAC8) selective inhibition reveals specific active site structural and functional determinants","volume":"61","author":"Sippl","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113971_bib60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-4939-7231-9_4","article-title":"Protein structure modeling with MODELLER","volume":"1654","author":"Webb","year":"2017","journal-title":"Methods Mol. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421008205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421008205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:36:42Z","timestamp":1759329402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421008205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":60,"alternative-id":["S0223523421008205"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113971","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor activity of novel POLA1-HDAC11 dual inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113971"}}